These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20542845)
21. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Lieberman-Blum SS; Fung HB; Bandres JC Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983 [TBL] [Abstract][Full Text] [Related]
22. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. Treviño A; Soriano V; Poveda E; Parra P; Cabezas T; Caballero E; Roc L; Rodríguez C; Eiros JM; Lopez M; De Mendoza C; J Antimicrob Chemother; 2014 Aug; 69(8):2191-4. PubMed ID: 24788659 [TBL] [Abstract][Full Text] [Related]
23. Clinical utility of maraviroc. Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. Hornberger J; Kilby JM; Wintfeld N; Green J AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010 [TBL] [Abstract][Full Text] [Related]
25. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170 [TBL] [Abstract][Full Text] [Related]
26. [Maraviroc efficacy in clinical studies on the development of the molecule]. Moreno S; Hernández B; Gutiérrez C; Delsol E Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A; Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395 [TBL] [Abstract][Full Text] [Related]
30. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282 [TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. Broder MS; Chang EY; Bentley TG; Juday T; Uy J J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058 [TBL] [Abstract][Full Text] [Related]
32. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Yost R; Pasquale TR; Sahloff EG Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831 [TBL] [Abstract][Full Text] [Related]